Daiwa Securities Group’s Puma Biotechnology PBYI Stock Holding History

Daiwa Securities Group’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-87	Closed	–	–	1365
2022 Q3	$0	Hold	87	–	–	﹤0.01%	1375
2022 Q2	$0	Hold	87	–	–	﹤0.01%	1409
2022 Q1	$0	Hold	87	–	–	﹤0.01%	1405
2021 Q4	$0	Hold	87	–	–	﹤0.01%	1431
2021 Q3	$1K	Hold	87	–	–	﹤0.01%	1278
2021 Q2	$1K	Hold	87	–	–	﹤0.01%	1206
2021 Q1	$1K	Hold	87	–	–	﹤0.01%	1215
2020 Q4	$1K	Sell	87 -156	-64%	-$1.58K	﹤0.01%	1194
2020 Q3	$2K	Hold	243	–	–	﹤0.01%	1142
2020 Q2	$2K	Hold	243	–	–	﹤0.01%	1162
2020 Q1	$2K	Hold	243	–	–	﹤0.01%	1161
2019 Q4	$2K	Hold	243	–	–	﹤0.01%	1165
2019 Q3	$3K	Hold	243	–	–	﹤0.01%	1103
2019 Q2	$3K	Hold	243	–	–	﹤0.01%	1132
2019 Q1	$9K	Buy	243 +36	+17%	+$1.1K	﹤0.01%	1040
2018 Q4	$4K	Hold	207	–	–	﹤0.01%	1074
2018 Q3	$9K	Hold	207	–	–	﹤0.01%	1050
2018 Q2	$12K	Sell	207 -21,487	-99%	-$1.25M	﹤0.01%	1042
2018 Q1	$1.48M	Buy	21,694 +1,950	+10%	+$146K	0.01%	422
2017 Q4	$1.95M	Buy	+19,744	New	+$2.21M	0.01%	385

Other funds holding PBYI

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

HIM

Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Daiwa Securities Group's PBYI Position: Q4 2022 in Review

Daiwa Securities Group sold out of Puma Biotechnology (PBYI) in Q4 2022, closing a stake of 87 shares.

Daiwa Securities Group first reported a position in PBYI in Q4 2017 and held it in 20 quarters. The position peaked at $1.95M in Q4 2017. 88 funds tracked by Wall St. Rank hold PBYI as of Q4 2022.

Daiwa Securities Group reported no remaining Puma Biotechnology position as of Q4 2022 after selling out during the quarter.
Daiwa Securities Group sold 87 Puma Biotechnology shares in Q4 2022.
Daiwa Securities Group first reported a position in Puma Biotechnology in Q4 2017 and held it in 20 quarters.
Daiwa Securities Group's Puma Biotechnology position peaked at $1.95M in Q4 2017.
88 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2022.

Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.